ProQuest www.csa.com
 
About CSA Products Support & Training News and Events Contact Us
 
RefWorks
  
Discovery Guides Areas
>
>
>
>
>
 
  
e-Journal

 

Cancer Vaccines
(Released January 2006)

 
  by Preeti Gokal Kochar  

Review

Key Citations

Web Sites

Glossary

Conferences

Editor
 
Key Citations Short Format Full Format
  1. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer
    Vaccine, Vol. 23, No. 17-18, Mar 2005, pp. 2374-2378

  2. Migration of dendritic cell based cancer vaccines: in vivo veritas?
    Current opinion in immunology, Vol. 17, No. 2, Apr 2005, pp. 170-174

  3. Regulators of Apoptosis: Suitable Targets for Immune Therapy of Cancer
    Nature Reviews: Drug Discovery, Vol. 4, No. 5, May 2005, pp. 399-409

  4. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2
    Clinical Immunology, Vol. 114, No. 1, Jan 2005, pp. 70-78

  5. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment
    FEMS microbiology letters, Vol. 246, No. 1, 1 May 2005, pp. 67-73

  6. Identification of Noncanonical Melanoma-Associated T Cell Epitopes for Cancer Immunotherapy
    Journal of Immunology, Vol. 174, No. 11, 1 Jun 2005, pp. 6716-6724

  7. Altered intracellular sorting signals do not influence the efficacy of genetic melanoma vaccines incorporating helper determinants in mice
    Journal of Gene Medicine, Vol. 7, No. 5, May 2005, pp. 613-620

  8. Electroporation as a "Prime/Boost" Strategy for Naked DNA Vaccination against a Tumor Antigen
    Journal of Immunology, Vol. 174, No. 10, May 2005, pp. 6292-6298

  9. Exosomes: A new delivery system for tumor antigens in cancer immunotherapy
    International Journal of Cancer, Vol. 114, No. 4, 2005, pp. 613-622

  10. Immune-Reconstituted Influenza Virosome Containing CD40L Gene Enhances the Immunological and Protective Activity of a Carcinoembryonic Antigen Anticancer Vaccine
    Journal of Immunology, Vol. 174, No. 11, 1 Jun 2005, pp. 7210-7216

  11. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination
    Proceedings of the National Academy of Sciences, USA, Vol. 102, No. 11, 15 Mar 2005, pp. 4185-4190

  12. Presentation of Endogenously Synthesized MHC Class II-Restricted Epitopes by MHC Class II Cancer Vaccines Is Independent of Transporter Associated with Ag Processing and the Proteasome
    Journal of Immunology, Vol. 174, No. 4, 15 Feb 2005, pp. 1811-1819

  13. A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour
    Cancer Immunology, Immunotherapy, Vol. 54, No. 2, Feb 2005, pp. 157-171

  14. DNA Vaccines: Progress and Challenges
    Journal of Immunology, Vol. 175, No. 2, Jul 2005, pp. 633-639

  15. IL-4-Transfected Tumor Cell Vaccines Activate Tumor-Infiltrating Dendritic Cells and Promote Type-1 Immunity
    Journal of Immunology, Vol. 174, No. 11, 1 Jun 2005, pp. 7194-7201

  16. CD4 T cells in tumor immunity
    Springer seminars in immunopathology, Vol. 27, No. 1, Jun 2005, pp. 37-48

  17. Gene Therapy to Manipulate Effector T Cell Trafficking to Tumors for Immunotherapy
    Journal of Immunology, Vol. 174, No. 9, 1 May 2005, pp. 5766-5773

  18. T-cell triggering by CD3-and CD28-binding molecules linked to a human virus-modified tumor cell vaccine
    Vaccine, Vol. 23, No. 19, Mar 2005, pp. 2439-2453

  19. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo
    Nature medicine, Vol. 11, No. 2, 2005, pp. 130-137

  20. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo
    Nature medicine, Vol. 11, No. 2, Feb 2005, pp. 130-137

  21. Cancer vaccines and immunotherapies: emerging perspectives
    Vaccine, Vol. 23, No. 17-18, Mar 2005, pp. 2359-2362

  22. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma
    Cancer gene therapy, Vol. 12, No. 8, Aug 2005, pp. 699-707

  23. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn
    Cancer Immunology, Immunotherapy, Vol. 54, No. 5, May 2005, pp. 424-430

  24. Modification of Professional Antigen-Presenting Cells with Small Interfering RNA In vivo to Enhance Cancer Vaccine Potency
    Cancer research, Vol. 65, No. 1, Jan 2005, pp. 309-316

  25. Rapid Assessment of Recognition Efficiency and Functional Capacity of Antigen-Specific T-Cell Responses
    Journal of Immunotherapy, Vol. 28, No. 4, Jul-Aug 2005, pp. 297-305

  26. Immunotherapy for Pancreatic Cancer : Science Driving Clinical Progress
    Nature Reviews: Cancer, Vol. 5, No. 6, Jun 2005, pp. 459-467

  27. Surrogate Tumor Antigen Vaccination Induces Tumor-Specific Immunity and the Rejection of Spontaneous Metastases
    Cancer research, Vol. 65, No. 7, 1 Apr 2005, pp. 2938-2946

  28. Recombinant NY-ESO-1 Cancer Antigen: Production and Purification under cGMP Conditions
    Preparative Biochemistry and Biotechnology, Vol. 35, No. 2, 2005, pp. 119-134

  29. CpG Oligonucleotide Therapy Cures Subcutaneous and Orthotopic Tumors and Evokes Protective Immunity in Murine Bladder Cancer
    Journal of Immunotherapy, Vol. 28, No. 1, Jan 2005, pp. 20-27

  30. Breaking tolerance in cancer immunotherapy: time to ACT
    Current opinion in immunology, Vol. 17, No. 2, Apr 2005, pp. 187-194

  31. Measuring Melanoma-Specific Cytotoxic T Lymphocytes Elicited by Dendritic Cell Vaccines with a Tumor Inhibition Assay In Vitro
    Journal of Immunotherapy, Vol. 28, No. 2, Mar 2005, pp. 148-157

  32. Targeted Delivery of the ErbB2/HER2 Tumor Antigen to Professional APCs Results in Effective Antitumor Immunity
    Journal of Immunology, Vol. 174, No. 9, 1 May 2005, pp. 5481-5489

  33. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct
    British journal of cancer, Vol. 92, No. 8, 25 Apr 2005, pp. 1421-1429

  34. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence
    International Journal of Cancer, Vol. 113, No. 2, 20 Jan 2005, pp. 259-266

  35. Linked Foreign T-Cell Help Activates Self-Reactive CTL and Inhibits Tumor Growth
    Journal of Immunology, Vol. 175, No. 1, 1 Jul 2005, pp. 329-334

  36. Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver
    International Journal of Cancer, Vol. 113, No. 4, 2005, pp. 670-677

  37. Modulation of antitumor responses by dendritic cells
    Springer seminars in immunopathology, Vol. 26, No. 3, Jan 2005, pp. 329-341

  38. Vaccination of Apoptotic Fas Ligand-expressing Tumors Decreased Antitumor Responses by Enhanced Production of Immunosuppressive Cytokines
    Anticancer Research, Vol. 25, No. 1A, Jan-Feb 2005, pp. 299-304

  39. Understanding the response to immunotherapy in humans
    Springer seminars in immunopathology, Vol. 27, No. 1, Jun 2005, pp. 105-117

  40. Hsp70-Like Protein 1 Fusion Protein Enhances Induction of Carcinoembryonic Antigen-Specific CD8 super(+) CTL Response by Dendritic Cell Vaccine
    Cancer research, Vol. 65, No. 11, 1 Jun 2005, pp. 4947-4954

  41. MUC1 Peptide Vaccination in Patients with Advanced Pancreas or Biliary Tract Cancer
    Anticancer Research, Vol. 25, No. 5, Sep-Oct 2005, pp. 3575-3580

  42. Diverse CD8 super(+) T-Cell Responses to Renal Cell Carcinoma Antigens in Patients Treated with an Autologous Granulocyte-Macrophage Colony-Stimulating Factor Gene-Transduced Renal Tumor Cell Vaccine
    Cancer research, Vol. 65, No. 3, 1 Feb 2005, pp. 1079-1088